Psychologists in Glenville, WV Accepting Medicare
2 Psychologists found. Showing 1 - 2
 Charles Lee Chandler, MA, EDS Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 201 N Court St, Glenville, WV 26351 Phone: 304-462-7386 Fax: 304-462-5103 |
 Kaitlin Morrison Frymier Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 809 Medical Dr, Glenville, WV 26351 Phone: 304-624-6554 Fax: 304-624-5223 |
News Archive
Filing of Clinical Data's NDA for vilazodone accepted for FDA review
Clinical Data, Inc., today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for vilazodone for the treatment of major depressive disorder.
Study demonstrates impact of epilepsy on child and parent sleep patterns
Researchers from Massachusetts General Hospital for Children in Boston have determined that pediatric epilepsy significantly impacts sleep patterns for the child and parents. According to the study available in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy (ILAE), sharing a room or co-sleeping with their child with epilepsy decreases the sleep quality and prevents restful sleep for parents.
Using clopidogrel, PPIs increases cardiac damage risk: Study
Patients with coronary artery disease undergoing stent implantation are often prescribed the antiplatelet drug, clopidogrel. This drug prevents blood clots, but is known to have a side-effect that can cause stomach bleeding. Consequently, many users are also prescribed a proton pump inhibitor (PPI). Now, however, a meta-analysis of almost 160,000 patients carried out at the Medical University of Vienna and Wilhelminenhospital, Vienna, has shown that simultaneous use of these drugs can increase the risk of cardiac damage.
Phase 1 clinical trial of OXY111A initiated
NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.
Anesthesia-associated mortality rises again
In pure numerical terms, anesthesia-associated mortality has risen again. The reasons for this are the disproportionate increase in the numbers of older and multimorbid patients and surgical procedures that would have been unthinkable in the past.
› Verified 6 days ago